|Bid||0.00 x 1800|
|Ask||0.00 x 800|
|Day's range||27.63 - 29.56|
|52-week range||24.24 - 72.51|
|Beta (5Y monthly)||1.71|
|PE ratio (TTM)||N/A|
|Earnings date||10 May 2021 - 14 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||46.53|
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020, inclusive (the "Class Period") of the important April 13, 2021 lead plaintiff deadline.
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m. ET.
Results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of bluebird bio, Inc. (Nasdaq: BLUE) and Bristol Myers Squibb’s (NYSE: BMY) investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, idecabtagene vicleucel (ide-cel; bb2121), in adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, were published today in The New England Journal of Medicine.1